Solicited local reactions the first 3 weeks following vaccination.

Mild: Not interfering with daily activity.
Moderate: Interfering with daily activity.
Severe: Preventing in engaging in daily activity.
*The number of women who experienced pain as an adverse event were significantly less in the group vaccinated with the 15 µg non-adjuvanted vaccine, than in the other groups (P<0.000001, Fisher's exact test).
**The number of women who experienced erythema as an adverse event were significantly less in the group vaccinated with the 15 µg non-adjuvanted vaccine, than in the other groups (P = 0.03, Fisher's exact test).
***The number of women who experienced pain as an adverse event were significantly less in the group vaccinated with the 15 µg non-adjuvanted vaccine, than in the other groups (P = 0.008, Fisher's exact test).

轻度（Mild）：不影响日常活动。
中度（Moderate）：对日常活动产生干扰。
重度（Severe）：无法参与日常活动。
* 接种15μg非佐剂疫苗（non-adjuvanted vaccine）的组别中，出现疼痛不良反应的女性人数显著低于其他组别（P<0.000001，费希尔精确检验（Fisher's exact test））。
** 接种15μg非佐剂疫苗的组别中，出现红斑（erythema）不良反应的女性人数显著低于其他组别（P=0.03，费希尔精确检验）。
*** 接种15μg非佐剂疫苗的组别中，出现疼痛不良反应的女性人数显著低于其他组别（P=0.008，费希尔精确检验）。